PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, Saeed Aslani, Malihe Alimardani, Alireza Pasdar, Amirhossein Sahebkar*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

79 Citations (Scopus)

Abstract

Over the course of past few years, cancer immunotherapy has been accompanied with promising results. However, preliminary investigations with respect to immunotherapy concentrated mostly on targeting the immune checkpoints, nowadays, emerge as the most efficient strategy to raise beneficial antitumor immune responses. Programmed cell death protein 1 (PD-1) plays an important role in subsiding immune responses and promoting self-tolerance through suppressing the activity of T cells and promoting differentiation of regulatory T cells. PD-1 is considered as an immune checkpoint and protects against autoimmune responses through both induction of apoptosis in antigen-specific T cells and inhibiting apoptosis in regulatory T cells. Several clinical trials exerting PD-1 monoclonal antibodies as well as other immune-checkpoint blockades have had prosperous outcomes and opened new horizons in tumor immunotherapy. Nonetheless, a bulk of patients have failed to respond to these newly emerging immune-based approach and the survival rate was not satisfying. Additional strategies, especially combination therapies, has been initiated and been further promising. Attempts to identify novel and well-suited predictive biomarkers are also sensed. In this review, the promotion of cancer immunotherapy targeting PD-1 immunoinhibitory pathway is discussed.

Original languageEnglish
Pages (from-to)16824-16837
Number of pages14
JournalJournal of Cellular Physiology
Volume234
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • cancer therapy
  • immune checkpoint
  • monoclonal antibody
  • PD-1
  • PD-L-1
  • CD8(+) T-CELLS
  • PD-1 BLOCKADE
  • SOLID TUMORS
  • ANTI-PD-L1 ANTIBODY
  • IMMUNE CHECKPOINTS
  • ANTITUMOR IMMUNITY
  • ADVANCED MELANOMA
  • ADVERSE EVENTS
  • OPEN-LABEL
  • B7 FAMILY

Cite this